通过 Lysosomal-Responsive SN38-G 负载脂质体,安全有效地在细胞内释放 SN38
Pierre-Alain Burnouf1, Yu-Cheng Su2, Shih-Hung Yang3
1International Center for Wound Repair and Regeneration, National Cheng-Kung University, Tainan 704, Taiwan.
ACS applied bio materials
|July 8, 2025
概括
这项研究提出了一种新的脂质体药物递送方法,用于疏水性化疗. 通过封装水友性前药衍生物,它实现了高药载荷和持续释放,增强治疗潜力.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 由于药物聚合和脂质体不稳定,脂质体配方在提供强效,疏水性化疗剂方面受到限制.
- 疏水性药物往往在脂质体内保持不良,这挑战了它们的疗效.
- 开发有效的疏水药物输送系统对于推进癌症化疗至关重要.
研究的目的:
- 开发一种新型的脂质体配方,以有效地输送疏水性药物,特别是SN38,氨酸的活性代谢物.
- 克服当前脂肪体配方在封装和保留强效疏水性化疗药物的局限性.
- 展示一种新的策略,通过脂质体实现高药载荷和持续释放疏水性药物.
主要方法:
- 合成的SN38葡萄化物 (SN38-G) 的两性衍生物,即SN38-Gmet和SN38-Geth,来自水友性前药物.
- 将这些两衍生物封装成具有内部性pH的脂质体.
- 在模拟体液中研究了37°C的药物保留稳定性,并通过 lysosomal beta-glucuronidase介导的体外细胞毒性进行了评估.
主要成果:
- 在封装的疏水性药物衍生物中,药物与脂的高摩尔比率超过60%.
- 在模拟的体液中,在37°C的温度下,药物持续保留超过15天.
- 证实,脂质体配方通过依赖于 lysosomal beta-glucuronidase 的途径释放活性 SN38,诱导细胞毒性.
结论:
- 开发的脂质体配方有效封装和保留疏水性药物,克服了以前的局限性.
- 这种新的方法可以实现高药物负载和持续释放,显示出强大的疏水性化疗药物的前景.
- 使用水友性前药衍生物和内部水解的策略为具有挑战性的药物输送应用提供了一个多功能平台.
关键词:
SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN38SN化疗 化疗是一种化学疗法.药物输送是药物输送的过程.葡萄糖化物 葡萄糖化物脂质体是一种脂质体.更多相关视频
10:58SNARE-mediated Fusion of Single Proteoliposomes with Tethered Supported Bilayers in a Microfluidic Flow Cell Monitored by Polarized TIRF Microscopy
Published on: August 24, 2016
11.0K
06:58Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles
Published on: October 18, 2024
816
相关概念视频
01:43SNAREs and Membrane Fusion
13.6K
Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
13.6K
01:24Modified-Release Drug Delivery Systems: Site-Targeted
113
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
113